Glucotrack, Inc. - 8-K Filing
Glucotrack, Inc. submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) on May 7, 2026, to initiate a U.S. clinical study for its fully implantable continuous blood glucose monitoring (CBGM) technology. The submission marks progress in the development of a long-term, implantable glucose monitoring system designed to provide real-time, blood-based accuracy without an on-body wearable. The company plans to proceed with the clinical study following FDA approval. (Items: 7.01 Regulation FD Disclosure On May 7, 2026, Glucotrack, Inc, 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No)
Tickers: $GCTK